CRITICAL PATH INSTITUTE ANNOUNCES APPOINTMENTS OF PETER HUTT, ALAN LEVIN, AND PAULA OLSIEWSKI TO ITS BOARD OF DIRECTORS
Peter Barton Hutt, LLB, LLM
Peter Barton Hutt is a nationally recognized expert in food and drug law, having served as Chief Counsel for the U.S. Food and Drug Administration from 1971-1975, and having taught the subject at Harvard Law School since 1994. Mr. Hutt co-authored the reference volume Food and Drug Law: Cases and Materials, and has participated in the drafting of most of the major legislation amending the Federal Food, Drug, and Cosmetic Act since 1962. He has testified before the U.S. House and Senate more than 100 times and has been a member of the Institute of Medicine of the National Academy of Sciences since its formation in 1971. Mr. Hutt received his Master of Laws from New York University, his Bachelor of Laws from Harvard Law School, and his Bachelor of Arts from Yale University.
Alan G. Levin, MS, CPA
Alan Levin brings to C-Path many years of international finance, capital markets, and business operations experience in the pharmaceutical industry. He has served in numerous senior leadership positions, including Chief Financial Officer of Pfizer Inc and Endo Health Solutions. He currently serves on the boards of several life sciences organizations, including Aceto Corporation, Auven Therapeutics, and Diffusion Pharmaceuticals. Mr. Levin is a Certified Public Accountant and earned his Master of Science in accounting from New York University’s Stern School of Business and a Bachelor of Arts from Princeton University.
Paula J. Olsiewski, PhD
Paula J. Olsiewski has a long and distinguished career serving the biotech and biomedical communities in many capacities. She created and directs the Alfred P. Sloan Foundation’s programs in Microbiology of the Built Environment and Synthetic Biology; she directed the New York City Biotechnology Initiative to help biotech companies grow by fostering relationships between academia and industry; and she served as Vice President of Product Development at Enzo Biochem, Inc. She serves on numerous boards, most notably as Chair of the Board of Scientific Counselors Homeland Security Research Subcommittee, U.S. Environmental Protection Agency. Dr.
Olsiewski received a Doctor of Philosophy in biological chemistry from the Massachusetts Institute of Technology and a Bachelor of Science in chemistry from Yale University.
“We are honored to welcome these three new directors to our Board, and look forward to applying their diverse skills and experiences to C-Path’s expanding competencies,” said Dr. Peter B. Corr, Chair of C-Path’s Board. “As our mission naturally leads us into new partnerships, new areas of disease research, and new clinical and regulatory challenges, their expertise, and that of our entire diverse and accomplished Board, will be very valuable.”
For full biographies of the C-Path Board of Directors, click here.
About the Critical Path Institute:
C-Path (Critical Path Institute) is an independent, non-profit organization established in 2005 with public and private philanthropic support from the Arizona community, Science Foundation Arizona, and the U.S. Food and Drug Administration (FDA). C-Path’s mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. An international leader in forming collaborations, C-Path has established nine global, public-private partnerships that currently include over 1,000 scientists from government and regulatory agencies, academia, patient advocacy organizations, and dozens of major pharmaceutical companies. C-Path is headquartered in Tucson, Arizona.
For more information, visit www.c-path.org.